63. 特発性血小板減少性紫斑病 [臨床試験数:311,薬物数:185(DrugBank:39),標的遺伝子数:43,標的パスウェイ数:132

Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-004683-22-NO16/10/202029/04/2020Daratumumab as a treatment for adult immune thrombocytopeniaDaratumumab as a treatment for adult immune thrombocytopenia - The DART-study Immune thrombocytopenia
MedDRA version: 23.0Level: LLTClassification code 10021245Term: Idiopathic thrombocytopenic purpuraSystem Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: daratumumab
INN or Proposed INN: DARATUMUMAB
Other descriptive name: HUMAX-CD38
Ostfold Hospital TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 2Norway